Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

Lucia Vrablova, Xiaoshuai Zhang, Eva Kriegova, Milos Kudelka, Martin Radvansky, Sen Yang, Jaroslava Juranova, Tomas Papajik, Robert Peter Gale, Qian Jiang, Edgar Faber

Blood (2023) 142 (Supplement 1): 6374.

https://doi.org/10.1182/blood-2023-187548

Published: 2023

Journal Articles

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Blood (2023) 142 (Supplement 1): 3166.

https://doi.org/10.1182/blood-2023-174455

Published: 2023

Journal Articles

Clinical Impact of Basophilia during Cytoreduction in Patients with Chronic Myeloid Leukaemia

Lucia Vrablova, Lucia Hrbcekova, Eva Kriegova, Martin Radvansky, Tomas Papajik, Jiri Minarik, Martina Divoka, Milena Holzerova, Romana Janska, Martin Cernan, Edgar Faber

Blood (2022) 140 (Supplement 1): 12229–12230.

https://doi.org/10.1182/blood-2022-168996

Published: 2022

Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Blood (2022) 140 (Supplement 1): 818–820.

https://doi.org/10.1182/blood-2022-162252

Published: 2022

Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Blood (2021) 138 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2021-146221

Published: 2021

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party

Blood (2018) 132 (Supplement 1): 4390.

https://doi.org/10.1182/blood-2018-99-118490

Published: 2018

Journal Articles

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

Carmen Martinez, MD PhD, Ariane Boumendil, PhD, Joanna Romejko-Jarosinska, Achilles Anagnostopoulos, Edgar Faber, MD, Xavier Poire, MD, Ibrahim Yakoub-Agha, MD PhD, Saad Akhtar, MD, Gunhan Gurman, Vincenzo Pavone, Kazimierz Halaburda, Aida Botelho Sousa, Herv Ghesquieres, Hervé Finel, Irma Khvedelidze, Silvia Montoto, MD, Anna Sureda, MD

Blood (2018) 132 (Supplement 1): 3429.

https://doi.org/10.1182/blood-2018-99-112180

Published: 2018

Journal Articles

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

Jiri Minarik, MD PhD, Edgar Faber, MD, Ludek Raida, MD PhD, Tomas Szotkowski, MD, Jaroslav Bacovsky, Tomas Pika, MD PhD, Ivana Skoumalova, MD PhD, Petra Krhovska, Jana Zapletalova, Mgr., PhD, Tomas Papajik, MD prof, Vlastimil Scudla, Prof, MD CSc

Blood (2018) 132 (Supplement 1): 5749.

https://doi.org/10.1182/blood-2018-99-112115

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Blood (2016) 128 (22): 522.

https://doi.org/10.1182/blood.V128.22.522.522

Published: 2016

Journal Articles

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Shady Adnan, MD MSc, Leopold Sellner, MD, Dorine Bellanger, Alexandra Schrader, Giuliano Crispatzu, Henan Zhang, MD, Carlos C Mateos, PhD, Edgar Faber, MD PhD, Steffen Koschmieder, MD, Tim H. Brummendorf, MD PhD, Krister Wennerberg, PhD, Wei Ding, MD PhD, Marc-Henri Stern, MD PhD, Marco Herling, MD, Simon Anders, PhD, Wolfgang Huber, PhD, Thorsten Zenz, MD, Satu Mustjoki, MD, PhD

Blood (2015) 126 (23): 315.

https://doi.org/10.1182/blood.V126.23.315.315

Published: 2015

Journal Articles

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study

Racil Zdenek, Petra Belohlavkova, Petr Cetkovsky, Edgar Faber, Hana Klamova, Malaskova Ludmila, Tomasz Sacha, MD PhD, Voglova Jaroslava, Daniela Zackova, Pavel Zak, Jiri Mayer

Blood (2014) 124 (21): 1813.

https://doi.org/10.1182/blood.V124.21.1813.1813

Published: 2014

Journal Articles

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Emma I Andersson, MSc, Leopold Sellner, MD, Malgorzata Oles, Tea Pemovska, MSc, Paavo Pietarinen, MSc, Anneli Lauhio, MD, Katarzyna Tomska, Carlos Cuesta-Mateos, MD PhD, Edgar Faber, Tim H. Brummendorf, MD PhD, Olli Kallioniemi, MD PhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD, Wolfgang Huber, PhD, Krister Wennerberg, PhD, Thorsten Zenz, MD, Satu Mustjoki, MDPhD

Blood (2014) 124 (21): 917.

https://doi.org/10.1182/blood.V124.21.917.917

Published: 2014

Journal Articles

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Emma I Andersson, MSc, Tea Pemovska, MSc, Samuli Eldfors, MSc, Anneli Lauhio, MD, Paavo Pietarinen, MSc, Edgar Faber, MD, PhD, Olli Kallioniemi, MD, PhD, Krister Wennerberg, PhD, Caroline Heckman, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 3828.

https://doi.org/10.1182/blood.V122.21.3828.3828

Published: 2013

Journal Articles

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Mette Matilda Ilander, MSc, Anna Kreutzman, PhD, Peter Rohon, MD, Teresa Melo, MD, Edgar Faber, MD, PhD, Kimmo Porkka, MD, PhD, Jukka Vakkila, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2012) 120 (21): 2782.

https://doi.org/10.1182/blood.V120.21.2782.2782

Published: 2012

Journal Articles

Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,

Jelena D. Milosevic, Filip Razga, Dana Dvorakova, Tomas Jurcek, Tiina Berg, Ana Puda, Thorsten Klampfl, Ashot Harutyunyan, Bettina Gisslinger, Heinz Gisslinger, MD, Ester Orlandi, Paolo Bernasconi, Karel Indrak, Martina Divoka, Edgar Faber, Jiri Mayer, MD, Zdenek Racil, Robert Kralovics, PhD

Blood (2011) 118 (21): 3755.

https://doi.org/10.1182/blood.V118.21.3755.3755

Published: 2011

Journal Articles

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Blood (2010) 116 (21): 1239.

https://doi.org/10.1182/blood.V116.21.1239.1239

Published: 2010

Journal Articles

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Anna Kreutzman, MSc, Peter Rohon, MD, Edgar Faber, MD, PhD, Karel Indrak, MD, PhD, Vesa Juvonen, PhD, Veli Kairisto, MD, PhD, Jaroslava Voglova, MD, Marjatta Sinisalo, MD, PhD, Emilia Flochova, MD, PhD, Petteri Arstila, MD, PhD, Kimmo Porkka, MD, PhD, Satu Mustjoki, MD, PhD

Blood (2010) 116 (21): 1201.

https://doi.org/10.1182/blood.V116.21.1201.1201

Published: 2010

NARROW

Blood Basophil Concentration at Diagnosis Corelates with Prognosis in Newly-Diagnosed Persons with Chronic Myeloid Leukaemia

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Clinical Impact of Basophilia during Cytoreduction in Patients with Chronic Myeloid Leukaemia

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Prognostic Value of a New Clinically-Based Classification System in Patients with CMML Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis of the EBMT Chronic Malignancies Working Party

Second Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma after a Previous Autograft: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation

20 Years of Transplant Program in Multiple Myeloma - a Single Centre Experience

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Identification of Baseline Characteristics That Predict Good Outcome of Allogeneic Hematopoietic Cell Transplantation in Young Chronic Lymphocytic Leukemia Patients - a Retrospective Analysis from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Subgroups of T-Cell Prolymphocytic Leukemia (T-PLL) Discovered By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study

Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling

Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing

Functional Characterization of T- and NK-Cells in Chronic Myeloid Leukemia Patients Treated with Interferon-α Monotherapy.

Cytogenetic Aberration Profile of Chronic Myeloid Leukemia and Its Dynamic Changes During Imatinib Therapy,

The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–2009.

Interferon Alpha Treated Patients with Chronic Myeloid Leukemia (CML) In Prolonged Complete Remission Have Increased Numbers of NK-Cells and Clonal Gamma-Delta T-Cells, and a Distinct Plasma Cytokine Profile.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only